Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PF 08046054

Next Previous
Drug Profile

PF 08046054

Alternative Names: PDL1V; PF-08046054; SGN-PDL1V

Latest Information Update: 24 Oct 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfizer
  • Developer Seagen
  • Class Antineoplastics; Auristatins; Drug conjugates; Immunoconjugates; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Cell death stimulants; Mitosis inhibitors; Programmed cell death-1 ligand-1 inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Non-small cell lung cancer
  • Phase I Solid tumours

Most Recent Events

  • 29 Sep 2025 Phase-III clinical trials in Non-small cell lung cancer (Late-stage disease, Inoperable/Unresectable, Metastatic disease, Second-line therapy or greater, Recurrent) in China (IV) (NCT07144280)
  • 22 Aug 2025 Pfizer plans a phase III trial for Non small cell lung cancer (Second-line therapy or greater, Late-stage disease, Inoperable/Unresectable) in August 2025 (IV, Infusion) (NCT07144280)
  • 30 May 2025 Interim efficacy and adverse events data from a phase I trial in Solid tumours presented at the 61st Annual Meeting of the American Society of Clinical Oncology (ASCO-2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top